title: A Multicenter Study on the Long-term Outcomes of Half-dose Photodynamic Therapy in Chronic Central Serous Chorioretinopathy.
abstract: OBJECTIVE
  To investigate long-term efficacy and prognostic factors of half-dose photodynamic therapy (PDT) in chronic central serous chorioretinopathy (CSCR).
  
  
  METHODS
  Retrospective multicenter interventional case series.
  
  
  METHODS
  Patients with chronic CSCR undergoing half-dose PDT between 2005 and 2011 were reviewed. Main outcome measures included resolution of serous retinal detachment (SRD) with single PDT, change in best-corrected visual acuities (BCVAs), and recurrence rate of CSCR at 36 months after PDT. Prognostic factors of visual outcome and recurrence of CSCR after PDT were identified with multivariate regression analysis.
  
  
  RESULTS
  A total of 136 eyes of 123 patients were followed up for 57.7 ± 16.2 months. At 36 months after PDT, 132 eyes (97.1%) achieved complete resolution of SRD with single PDT and 4 eyes (2.9%) had CSCR recurrence. The mean logMAR BCVA improved from 0.36 ± 0.29 (Snellen equivalent 20/46; range: 0.1-1.2) at baseline to 0.15 ± 0.23 at 36 months (Snellen equivalent 20/28; range: 0.1-1.5; P < .001) and 0.16 ± 0.24 (Snellen equivalent: 20/29; range: 0.1-1.5; P < .001) at final follow-up. Forty-four eyes (32.4%) had ≥3 lines of BCVA gain while 5 eyes (3.7%) had ≥3 lines of BCVA loss at 36 months after PDT. Nine eyes (6.6%) developed CSCR recurrence at final follow-up. Baseline BCVA was significantly associated with the BCVA (P = .009) and the improvement in BCVA (P < .001) at final follow-up. History of bilateral CSCR was significantly associated with CSCR recurrence at final follow-up (P = .036; odds ratio = 15.84, 95% confidence interval = 1.20-208.32). Eight eyes (5.9%) had complications related to PDT.
  
  
  CONCLUSIONS
  Chronic CSCR patients treated with half-dose PDT can achieve long-term stable visual acuity and resolution of SRD. Patients with chronic CSCR are recommended to undergo half-dose PDT before they have significant visual deterioration. Patients with bilateral CSCR are more likely to develop CSCR recurrence after half-dose PDT.
authors: Department of Ophthalmology and Visual Sciences, Prince of Wales Hospital, the Chinese University of Hong Kong, Kowloon, Hong Kong.
authors: Frank H P
authors: FH
authors: Lai
authors: Department of Ophthalmology and Visual Sciences, Hong Kong Eye Hospital, the Chinese University of Hong Kong, Kowloon, Hong Kong.
authors: Danny S
authors: DS
authors: Ng
authors: Department of Ophthalmology and Visual Sciences, Hong Kong Eye Hospital, the Chinese University of Hong Kong, Kowloon, Hong Kong.
authors: Malini
authors: M
authors: Bakthavatsalam
authors: Department of Ophthalmology and Visual Sciences, Prince of Wales Hospital, the Chinese University of Hong Kong, Kowloon, Hong Kong.
authors: Vesta C K
authors: VC
authors: Chan
authors: Department of Ophthalmology and Visual Sciences, Prince of Wales Hospital, the Chinese University of Hong Kong, Kowloon, Hong Kong.
authors: Alvin L
authors: AL
authors: Young
authors: Department of Ophthalmology and Visual Sciences, Hong Kong Eye Hospital, the Chinese University of Hong Kong, Kowloon, Hong Kong.
authors: Fiona O J
authors: FO
authors: Luk
authors: Department of Ophthalmology and Visual Sciences, Hong Kong Eye Hospital, the Chinese University of Hong Kong, Kowloon, Hong Kong.
authors: Chi Wai
authors: CW
authors: Tsang
authors: Department of Ophthalmology and Visual Sciences, Prince of Wales Hospital, the Chinese University of Hong Kong, Kowloon, Hong Kong; Department of Ophthalmology and Visual Sciences, Hong Kong Eye Hospital, the Chinese University of Hong Kong, Kowloon, Hong Kong. Electronic address: brelen.marten@googlemail.com.
authors: Mårten E
authors: ME
authors: Brelén
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D056833:Central Serous Chorioretinopathy / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D002908:Chronic Disease; D004396:Coloring Agents / Q000008:administration & dosage; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D006801:Humans; D007208:Indocyanine Green / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000008:administration & dosage*; D011166:Porphyrins / Q000008:administration & dosage*; D011379:Prognosis; D012008:Recurrence; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D000077362:Verteporfin; D014792:Visual Acuity / Q000502:physiology
chemical_list: D004396:Coloring Agents; D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin; D007208:Indocyanine Green